ClinicalTrials.gg
CompletedNCT06588296TOGETHER-PsAUpdated May 13, 2026

Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight

A Phase 3 interventional study of Ixekizumab and Tirzepatide in Psoriatic Arthritis and Obesity, sponsored by Eli Lilly and Company. Completed at 86 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
279
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 193 studies in Arthritis, Psoriatic with a site in United States — 29 open to participants now, 59 under way, 20 of them phase 3. Arthritis, Psoriatic · United States.

Enrollment
75th of 158
279 · median 237
Started
2024
with 10 others
Phase 3
71 of 193
4 open now
Registered
166th of 193
by date
Lead sponsor
5 of 193
Eli Lilly and Company

Among the 193 studies in Arthritis, Psoriatic with a site in United States, this one is the 75th largest by enrollment of the 158 interventional ones that give a count, is one of 11 that started in 2024, is one of 71 in phase 3, and was the 166th registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

29 of the 193 studies in Arthritis, Psoriatic with a site in United States are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 193 studies in Arthritis, Psoriatic with a site in United States, or all of them as a file.
02

Study summary

The main purpose of this study is to demonstrate that when participants with psoriatic arthritis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and tirzepatide concomitantly administered, participants see improvement in their psoriatic arthritis and achieve weight reduction compared to when receiving ixekizumab.

Participation in this study includes up to 12 visits and could last up to 61 weeks including screening, open label treatment period, and post-treatment follow-up period.

03

Conditions studied

  • Psoriatic Arthritis
  • Obesity
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have signs and/or symptoms or documented diagnosis of Psoriatic Arthritis (PsA) for at least 6 months and currently fulfilling the classification of Psoriatic Arthritis (CASPAR) criteria.
  • Have active PsA, defined as the presence of at least 3 of 68 tender joints and at least 3 of 66 swollen joints.
  • Have obesity, of ≥30 kilograms per meter squared (BMI ≥30 kg/m²) or overweight (BMI ≥27 to \<30 kg/m²) in the presence of at least 1 of these weight-related comorbid conditions (hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, or T2DM).

Exclusion criteria

Exclusion Criteria:

Medical Conditions

  • Have Type 1 Diabetes Mellitus (T1DM).
  • Have insulin-treated Type 2 Diabetes Mellitus (T2DM).
  • Have a prior or planned surgical treatment for obesity.
  • Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia (MEN) syndrome type 2.
  • Have active, or a history of inflammatory bowel disease (Crohn's or ulcerative colitis).
  • Have a diagnosis or history of malignant disease within the 5 years prior to randomization, with the following exceptions:

    • basal cell or squamous epithelial carcinomas of the skin that have been resected, with no evidence of disease for 3 years.
    • cervical carcinoma in situ, with no evidence of recurrence within the 5 years prior to randomization.
  • Have a serious disorder or illness other than PsA.
  • Have a history of chronic or acute pancreatitis.
  • Have any prior use of ixekizumab or tirzepatide.
  • Diagnosis of other inflammatory arthritis, such as Rheumatoid Arthritis (RA), ankylosing spondylitis, reactive arthritis, gout, or enteropathic arthritis.
  • Have a previous failure or intolerance to an interleukin 17 inhibitor (IL-17i) or glucagon-like peptide 1 (GLP-1) receptor agonists.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
279 participants (actual)

Study arms

  • Experimental
    Ixekizumab

    Ixekizumab administered subcutaneous (SC).

    Drug: Ixekizumab

  • Experimental
    Ixekizumab and Tirzepatide

    Ixekizumab concomitantly administered with tirzepatide SC.

    Drug: Ixekizumab · Drug: Tirzepatide

Interventions

  • Administered SC

    Also known as: LY2439821

  • Administered SC

    Also known as: LY3298176

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Simultaneously Achieved American College of Rheumatology (ACR) ACR50 and at Least a 10% Weight Reduction

    ACR50 is defined as at least 50% improvement in the ACR core set values. The percentage improvement in the ACR scores is determined by an improvement of at least 50% in the number of Tender Joint Count (TJC) (0-68) and Swollen Joint Count (SJC) (0-66) and an improvement of at least 50% in at least 3 of these 5 assessments: 1. Patient's Assessment of Arthritis Pain Visual Analog Scale (VAS) 2. Patient's Global Assessment of Disease Activity Numeric Rating Scale (PaGADA \_NRS) 3. Physician's Global Assessment of Disease Activity Numeric Rating Scale (PhGADA NRS) 4. Patient's Assessment of Physical Function as measured by the Health Assessment Questionnaire-Disability Index (HAQ-DI) or 5. Acute phase reactant as measured by High-Sensitivity C-Reactive Protein (hsCRP)

    Time frame: Baseline up to Week 36

Secondary outcomes

  1. Percentage of Participants Simultaneously Achieving American College of Rheumatology (ACR) ACR20 and at Least a 5% Weight Reduction

    ACR20 is defined as at least 20% improvement in the ACR core set values. The percentage improvement in the ACR scores is determined by an improvement of at least 20% in the number of TJC (0-68) and SJC (0-66) and an improvement of at least 20% in at least 3 of these 5 assessments: 1. Patient's Assessment of Arthritis Pain Visual Analog Scale (VAS) 2. Patient's Global Assessment of Disease Activity Numeric Rating Scale (PaGADA \_NRS) 3. Physician's Global Assessment of Disease Activity Numeric Rating Scale (PhGADA NRS) 4. Patient's Assessment of Physical Function as measured by the Health Assessment Questionnaire-Disability Index (HAQ-DI) or 5. Acute phase reactant as measured by High-Sensitivity C-Reactive Protein (hsCRP)

    Time frame: Baseline up to Week 36

  2. Percentage of Participants Achieving ACR50

    ACR50 is defined as at least 50% improvement in the ACR core set values. The percentage improvement in the ACR scores is determined by an improvement of at least 50% in the number of TJC (0-68) and SJC (0-66) and an improvement of at least 50% in at least 3 of these 5 assessments: 1. Patient's Assessment of Arthritis Pain Visual Analog Scale (VAS) 2. Patient's Global Assessment of Disease Activity Numeric Rating Scale (PaGADA \_NRS) 3. Physician's Global Assessment of Disease Activity Numeric Rating Scale (PhGADA NRS) 4. Patient's Assessment of Physical Function as measured by the Health Assessment Questionnaire-Disability Index (HAQ-DI) or 5. Acute phase reactant as measured by High-Sensitivity C-Reactive Protein (hsCRP)

    Time frame: Baseline up to Week 36

  3. Percentage of Participants Achieving at Least a 10% Weight Reduction

    Percentage of Participants Who Achieved at Least a 10% Weight Reduction

    Time frame: Baseline up to Week 36

07

Study locations

86 sites
  • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Avondale
    Avondale, Arizona 85392, United States
  • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Chandler
    Chandler, Arizona 85225, United States
  • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Flagstaff
    Flagstaff, Arizona 86001, United States
  • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Gilbert
    Gilbert, Arizona 85297, United States
  • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Glendale
    Glendale, Arizona 85306, United States
  • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Mesa
    Mesa, Arizona 85210, United States
  • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Phoenix PV
    Phoenix, Arizona 85032, United States
  • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Sun City
    Sun City, Arizona 85351, United States
  • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Tucson
    Tucson, Arizona 85704, United States
  • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Tucson Southeast
    Tucson, Arizona 85748, United States
  • Medvin Clinical Research - Apple Valley
    Apple Valley, California 92307, United States
  • Medvin Clinical Research - Covina
    Covina, California 91722, United States
  • Newport Huntington Medical Group
    Huntington Beach, California 92648, United States
  • Purushotham & Akther Kotha MD, Inc
    La Mesa, California 91942, United States
  • Medvin Clinical Research - Riverside
    Riverside, California 92508, United States
  • Rheumatology Center of San Diego
    San Diego, California 92128, United States
  • Medvin Clinical Research - Temecula
    Temecula, California 92592, United States
  • Cohen Medical Centers
    Thousand Oaks, California 91360, United States
  • Medvin Clinical Research - Tujunga
    Tujunga, California 91042, United States
  • Medvin Clinical Research - Whittier
    Whittier, California 90602, United States
  • Denver Arthritis Clinic
    Denver, Colorado 80230, United States
  • Clinical Research of West Florida, Inc. (Clearwater)
    Clearwater, Florida 33765, United States
  • NeoClinical Research
    Hialeah, Florida 33016, United States
  • South Florida Rheumatology
    Hollywood, Florida 33021, United States
  • Jacksonville Center for Clinical Research
    Jacksonville, Florida 32216, United States
  • Vida Clinical Research
    Kissimmee, Florida 34741, United States
  • Life Clinical Trials
    Margate, Florida 33063, United States
  • Suncoast Clinical Research, Inc.
    New Port Richey, Florida 34652, United States
  • Vitalia Medical Research
    Palm Beach Gardens, Florida 33410, United States
  • Sarasota Arthritis Center
    Sarasota, Florida 34239, United States
  • Clinical Research of West Florida
    Tampa, Florida 33606, United States
  • International Center for Research
    Tampa, Florida 33614, United States
  • Conquest Research
    Winter Park, Florida 32789, United States
  • Southeastern Rheumatology Alliance dba Arthritis Center of North Georgia
    Gainesville, Georgia 30501, United States
  • Atlanta Research Center for Rheumatology
    Marietta, Georgia 30060, United States
  • St. Luke's Clinic
    Boise, Idaho 83702, United States
  • Great Lakes Clinical Trials - Ravenswood
    Chicago, Illinois 60640, United States
  • Greater Chicago Specialty Physicians
    Schaumburg, Illinois 60195, United States
  • Arnold Arthritis & Rheumatology
    Skokie, Illinois 60076, United States
  • Willow Rheumatology and Wellness PLLC
    Willowbrook, Illinois 60527, United States
  • Qualmedica Research, LLC
    Evansville, Indiana 47715, United States
  • Alliance for Multispecialty Research, LLC
    Wichita, Kansas 67207, United States
  • Accurate Clinical Research, Inc
    Lake Charles, Louisiana 70605, United States
  • Klein & Associates, M.D., P.A.
    Cumberland, Maryland 21502, United States
  • Klein & Associates, M.D., P.A.
    Hagerstown, Maryland 21740, United States
  • NECCR PrimaCare Research
    Fall River, Massachusetts 02721, United States
  • Advanced Rheumatology, PC
    Okemos, Michigan 48864, United States
  • Saint Paul Rheumatology
    Eagan, Minnesota 55121, United States
  • AARA Clinical Research - Kansas City Physician Partners - North
    Kansas City, Missouri 64151, United States
  • Clinvest Headlands Llc
    Springfield, Missouri 65807, United States
  • Arthritis Consultants, Inc.
    St Louis, Missouri 63141, United States
  • Logan Health Research
    Kalispell, Montana 59901, United States
  • Physician Research Collaboration, LLC
    Lincoln, Nebraska 68516, United States
  • Albuquerque Center for Rheumatology
    Albuquerque, New Mexico 87102, United States
  • Inspire Santa Fe Medical Group
    Santa Fe, New Mexico 87505, United States
  • St. Lawrence Health System
    Canton, New York 13617, United States
  • Onsite Clinical Solutions, LLC - Brenner Ave
    Salisbury, North Carolina 28144, United States
  • Paramount Medical Research & Consulting, LLC
    Middleburg Heights, Ohio 44130, United States
  • RAO Research LLC
    Oklahoma City, Oklahoma 73116, United States
  • Essential Medical Research
    Tulsa, Oklahoma 74137, United States
  • Summit Headlands
    Portland, Oregon 97210, United States
  • Altoona Center For Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • West Tennessee Research Institute
    Jackson, Tennessee 38305, United States
  • AARA Clinical Research - Murfreesboro Medical Clinic
    Murfreesboro, Tennessee 37128, United States
  • Tekton Research, LLC.
    Austin, Texas 78745, United States
  • Accurate Clinical Management, LLC
    Baytown, Texas 77521, United States
  • Precision Comprehensive Clinical Research Solutions - Colleyville
    Colleyville, Texas 76034, United States
  • Arthritis Care of Texas
    Corpus Christi, Texas 78415, United States
  • AARA Clinical Research - Lone Star Arthritis and Rheumatology Associates - Fort Worth
    Fort Worth, Texas 76109, United States
  • Accurate Clinical Research, Inc
    Houston, Texas 77089, United States
  • Research Physicians Network, LLC
    Houston, Texas 77089, United States
  • AARA Clinical Research - Lone Star Arthritis and Rheumatology Associates - Irving
    Irving, Texas 75039, United States
  • Biopharma Informatic, LLC
    Katy, Texas 77494, United States
  • West Texas Clinical Research
    Lubbock, Texas 79424, United States
  • Valley Arthritis Center
    McAllen, Texas 78501, United States
  • SouthWest Rheumatology Research, LLC
    Mesquite, Texas 75150, United States
  • Advanced Rheumatology of Houston - Woodlands
    The Woodlands, Texas 77382, United States
  • DM Clinical Research - TRA
    Tomball, Texas 77375, United States
  • Overlake Arthritis and Osteoporosis Center
    Bellevue, Washington 98004, United States
  • Arthritis Northwest, PLLC
    Spokane, Washington 99204, United States
  • Rheumatology & Pulmonary Clinic
    Beckley, West Virginia 25801, United States
  • Centro Reumatologico Caguas
    Caguas, 00725, Puerto Rico
  • Reuviva Research Center
    Guaynabo, 00968, Puerto Rico
  • GCM Medical Group, PSC - Hato Rey Site
    San Juan, 00917, Puerto Rico
  • Caribbean Medical Research Center
    San Juan, 00918, Puerto Rico
  • Mindful Medical Research
    San Juan, 00918, Puerto Rico
08

References and documents

Publications

  • Merola JF, Mease P, Kivitz A, Sattar N, Coates LC, Aletaha D, Kartman CE, Fischer P, Sun L, Martinez-Osuna P, Kronbergs A, Prajapati P, Cardoso A, Genovese MC, Ogdie A. Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial. Arthritis Rheumatol. 2026 Mar 28. doi: 10.1002/art.70134. Online ahead of print. PubMed 41903163 ↗

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2024 to primary completion in Nov 2025, 13 months.

Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 13 months is below that.

Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2024
First posted
Sep 19, 2024
StartActual
Sep 24, 2024
Primary completionActual
Nov 18, 2025
CompletionActual
Apr 23, 2026
Last update
May 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06588296
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Sep 24, 2024
Primary completion
Nov 18, 2025
Completion
Apr 23, 2026
Last update
May 13, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion